History of Avanir

1988

Founded with focus

Avanir started out as Lidak Pharmaceuticals (Lidak) in 1988, developing research-based treatments to meet patients’ needs.

microscope-icon.png

1998

Becoming Avanir

Avanir changed its name from Lidak Pharmaceuticals to Avanir Pharmaceuticals.

2000

CNS at the Forefront

Avanir obtained NDA approval for its first pharmaceuticals products, Abreva®, an over-the-counter cold sore treatment.

humanbrain-icon.png

2010

NUEDEXTA® Approved

In October, we received an FDA approval for NUEDEXTA® (dextromethorphan hydrobromide and quinidine sulfate) with a 20/10 mg dose strength.

2011

NUEDEXTA® is launched in the United States

Nuedexta Logo
nuedexta-boxset.jpg

2012

R&D Progress

Avanir entered into a license agreement with Concert Pharmaceuticals, Inc. to develop and commercializedeuterium-modified dextromethorphan for disorders of the central nervous system.

concert-history.png
avanir-logo-history.png

2013

Entered into Agreement with OptiNose®

On July 2, Avanir announced a development and commercialization agreement with OptiNose® AS for a newinvestigational product for the acute treatment of migraine. 

otsuka-history.png

2015

Joining Otsuka

In 2015, Avanir became a subsidiary of Otsuka America, Inc., a holding company owned by Otsuka Pharmaceutical Co., Ltd. This move provided the support of a leading global pharmaceutical company while allowing our business to remain nimble and flexible.

2016

ONZETRA® Xsail® approved

(sumatriptan nasal powder) 11 mg per nosepiece

Avanir received FDA approval of ONZETRA® Xsail® in January and launched it in the United States market in May.

onzetra-device-red.jpg

Copyright: AVANIR, NUEDEXTA, ONZETRA XSAIL and Avanir logos are trademarks or registered trademarks of Avanir Pharmaceuticals, Inc. in the United States or other countries.  All other marks, logos and trade names are the trademarks of their respective owners and appear by permission of those owners.  You may not reproduce, download or otherwise use any such trademarks, service marks, logos or trade names without the prior written consent of Avanir Pharmaceuticals, Inc. or the appropriate owner thereof.  The use of names, trademarks, and logos not owned by Avanir Pharmaceuticals, Inc. does not imply endorsement of products and services associated therewith.

PID: MLR-COB-US-0019-0918